Well in vitro and in vivo animal data both show Her-2 kinase inhibitor is synergistic with herceptin, but it just doesn't work in human trials. However, If you cannot achieve similar serum concentration like seen in the animal data due to tolerability issue, I don't think you can rule out herceptin/her-2 kinase combo inhibition as a viable mechanism for breast cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.